DE69803052D1 - Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt - Google Patents

Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt

Info

Publication number
DE69803052D1
DE69803052D1 DE69803052T DE69803052T DE69803052D1 DE 69803052 D1 DE69803052 D1 DE 69803052D1 DE 69803052 T DE69803052 T DE 69803052T DE 69803052 T DE69803052 T DE 69803052T DE 69803052 D1 DE69803052 D1 DE 69803052D1
Authority
DE
Germany
Prior art keywords
tumors
progression
stop
active substance
therapeutic viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69803052T
Other languages
English (en)
Other versions
DE69803052T2 (de
Inventor
Alexander Fred Markham
David Mark Meredith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leeds
Original Assignee
University of Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leeds filed Critical University of Leeds
Application granted granted Critical
Publication of DE69803052D1 publication Critical patent/DE69803052D1/de
Publication of DE69803052T2 publication Critical patent/DE69803052T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69803052T 1997-02-27 1998-02-24 Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt Expired - Fee Related DE69803052T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9704046.3A GB9704046D0 (en) 1997-02-27 1997-02-27 Arrestable therapeutic
PCT/GB1998/000559 WO1998037905A1 (en) 1997-02-27 1998-02-24 Arrestable therapeutic viral agent

Publications (2)

Publication Number Publication Date
DE69803052D1 true DE69803052D1 (de) 2002-01-31
DE69803052T2 DE69803052T2 (de) 2002-07-25

Family

ID=10808384

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69803052T Expired - Fee Related DE69803052T2 (de) 1997-02-27 1998-02-24 Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt

Country Status (11)

Country Link
EP (1) EP0979093B1 (de)
JP (1) JP2001513634A (de)
AT (1) ATE210990T1 (de)
AU (1) AU6301398A (de)
CA (1) CA2280690A1 (de)
DE (1) DE69803052T2 (de)
DK (1) DK0979093T3 (de)
ES (1) ES2170479T3 (de)
GB (1) GB9704046D0 (de)
PT (1) PT979093E (de)
WO (1) WO1998037905A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60107203T3 (de) * 2000-01-21 2009-07-23 Biovex Ltd. Herpes-virusstämme für die gentherapie
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0668355B1 (de) * 1993-12-20 1999-04-07 Akzo Nobel N.V. Impstoff zum Schutze von Pferden gegen Pferdeherpesvirus-Infektionen
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
ZA966287B (en) * 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
GB9626029D0 (en) * 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors

Also Published As

Publication number Publication date
DE69803052T2 (de) 2002-07-25
EP0979093A1 (de) 2000-02-16
ES2170479T3 (es) 2002-08-01
JP2001513634A (ja) 2001-09-04
CA2280690A1 (en) 1998-09-03
GB9704046D0 (en) 1997-04-16
ATE210990T1 (de) 2002-01-15
DK0979093T3 (da) 2002-04-02
PT979093E (pt) 2002-06-28
EP0979093B1 (de) 2001-12-19
WO1998037905A1 (en) 1998-09-03
AU6301398A (en) 1998-09-18

Similar Documents

Publication Publication Date Title
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
ATE371372T1 (de) Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren
ATE500808T1 (de) Onkolytische virustherapie
DE69517957T2 (de) 5-substituierte derivate von mycophenolsäure
MXPA01010393A (es) Tratamiento de neoplasmas con virus.
ATE324119T1 (de) Verwendung von saccharid-konjugaten
DE69426334T2 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
DE602004020266D1 (de) Therapeutische und diagnostische anti-hsp 70-antikörper
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
TR200100637T2 (tr) Yeni doğal ürün türevleri
NO932101L (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
MD990258A (en) Method of treatment of the acute viral hepatitis B
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
DE60019104D1 (de) Gentherapy von lungenkrankheiten
ATE360062T1 (de) Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren
DK1150981T3 (da) Terapeutisk necleosidforbindelse
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
ITMI980179A1 (it) Proteine ricombinanti derivate da hgf e msp
TR200000916T2 (tr) İkameli piperidin türevleri.
WO2003034069A3 (en) Tcmp 03 protein for use in cancer therapy
DE60030593D1 (de) Labdan-enthaltende arzneiformulierungen zur behandlung von tumoren oder leukämien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee